Abivax SA, a Phase 3 biotechnology company dedicated to developing treatments to modulate the immune system and treat chronic inflammatory diseases, is delighted to welcome Dr. Sheldon Sloan, M.D., M. Bioethics, to the role of Chief Medical Officer, effective March 1, 2023. With an impressive 30-year background in academia and the biopharmaceutical industry, Dr. Sloan brings a wealth of knowledge and expertise in Gastroenterology and Inflammatory Bowel Disease (IBD) to Abivax. He has held high-ranking positions at J&J, Arena Pharmaceuticals and Pfizer, managing late-stage clinical trial programs, global submissions and product launches in the IBD field.
Abivax is delighted to welcome Sheldon to their team and to benefit from his immense experience and expertise. His specialized skills will be invaluable in conducting the Phase 3 clinical program with obefazimod for the treatment of UC patients, as well as in developing the strategy for future clinical development programs with obefazimod, primarily for Crohn’s disease. Abivax is excited to work together with Sheldon and to make obefazimod available to those who need it, should it be approved. The Abivax team is looking forward to combining their competencies and efforts with Sheldon to achieve their common goal.
Dr. Sloan is an accomplished leader in the pharmaceutical industry with a strong track record in bioethics. He holds an M.D. from Rush Medical College, Chicago, USA, and a Master of Bioethics from the University of Pennsylvania, USA. Dr. Sloan has held various leadership positions at J&J in Medical Affairs, R&D, and Science Policy, and was Global Medical Affairs Leader for IBD, responsible for the global launch strategy and execution for Crohn’s Disease and Ulcerative Colitis for Stelara. Most recently, he was Program Lead for Etrasimod UC at Arena Pharmaceuticals and, after its acquisition, for Pfizer, responsible for cross-functional leadership, planning and management, operational business process planning, and execution management of the Ulcerative Colitis program, including its global submission and launch. He has also authored numerous scientific publications and abstracts and contributed to various books in the gastroenterology and immunology fields. Currently, Dr. Sloan is at Abivax where he is working to develop innovative therapeutics for autoimmune diseases.
I am delighted to join Abivax and steer its late-stage clinical program with obefazimod for the treatment of UC through pivotal studies and, if successful, to global submissions and launch. As a medical and bioethics expert in the IBD field, I am thrilled to have the opportunity to contribute and make sure that obefazimod’s potential is fully realized for the benefit of those suffering from IBD and other chronic inflammatory diseases. This novel long-term therapy option could provide relief for so many and I am committed to ensuring its success.
Abivax is a pioneering biotechnology company, leading the way in the development of innovative therapeutics to treat inflammatory diseases. Founded by Truffle Capital, Abivax is listed on Euronext B (ISIN: FR0012333284 – Mnémo: ABVX) and their main drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for the treatment of ulcerative colitis. With headquarters in Paris and Montpellier, Abivax is committed to advancing safe and effective treatments to improve the lives of patients with chronic inflammatory diseases.